We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. More patients treated with upadacitinib achieved ...
(NASDAQ: ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health ...
To better determine the onset of symptom relief with alfuzosin 10 mg q.d. in men with symptomatic BPH, we conducted a short-term, randomized, controlled clinical trial. For this investigation, we used ...
Multicenter retrospective registry analysis (2018–2024; n=153) compared add-on initiation within 24 months (EIT; n=36) versus later (LIT) in AChR+ generalized MG. Early intensification drove rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results